Abstract: Novel peptide substrates hydrolysed by ADAM10 or ADAM17 are disclosed, as well as their applications in the diagnosis of diabetes or its complications.

Abstract: The invention relates to a novel chemical compound—a diagnostic marker—for use in medicine, more specifically in cancer diagnosis, in particular the diagnosis of biliary tract cancer. The invention also relates to an in vitro method for detecting enzymatic activity present in a subject's body fluid, in particular derived from biliary tract cancer cells, using the compound. The invention further relates to an in vitro method for diagnosing biliary tract cancer using the compound, a kit comprising the compound and use of the compound for the detection of enzymatic activity specific to biliary tract cancer and use of the compound for the diagnosis of biliary tract cancer. The invention also relates to the compound for use as a diagnostic marker of biliary tract cancer and a method for the treatment of biliary tract cancer comprising a step of carrying out the method for the diagnosis of biliary tract cancer as defined above using the compound.

Abstract: The invention provides a compound characterized by formula (1): X1-Thr-Thr-Ala-Arg-X2, wherein cleavage of the compound into a fragment 1 comprising X1 and a fragment 2 comprising X2 generates a detectable signal. The invention further provides an in vitro method for detecting protease activity in a subject's body fluid, comprising contacting the body fluid with the compound of the invention and detecting a signal, wherein the body fluid may comprise a hydrolytic enzyme derived from pancreatic cancer cells. Furthermore, the invention provides a kit comprising the compound of the invention and a measurement buffer. In addition, the invention provides the use of the compound, the in vitro method or the kit of the invention for the detection of pancreatic cancer, or for monitoring a subject that is suspected of having pancreatic cancer, has an increased risk of developing pancreatic cancer, or has had pancreatic cancer.

Abstract: The invention relates to a novel chemical compound—a diagnostic marker—for use in medicine, more specifically in cancer diagnosis, in particular the diagnosis of ovarian cancer. The invention also relates to an in vitro method for detecting enzymatic activity present in a subject's body fluid, in particular derived from ovarian cancer cells, using the compound. The invention further relates to an in vitro method for diagnosing ovarian cancer using the compound, a kit comprising the compound and use of the compound for the detection of enzymatic activity specific to ovarian cancer and use of the compound for the diagnosis of ovarian cancer. The invention also relates to the compound for use as a diagnostic marker of ovarian cancer and a method for the treatment of ovarian cancer comprising a step of carrying out the method for the diagnosis of ovarian cancer as defined above using the compound.

Abstract: The invention relates to a novel chemical compound—a diagnostic marker—for use in medicine, more specifically in cancer diagnosis, in particular the diagnosis of uterine body cancer. The invention also relates to an in vitro method for detecting enzymatic activity present in a subject's body fluid, in particular derived from uterine body cancer cells, using the compound. The invention further relates to an in vitro method for diagnosing uterine body cancer using the compound, a kit comprising the compound and use of the compound for the detection of enzymatic activity specific to uterine body cancer and use of the compound for the diagnosis of uterine body cancer. The invention also relates to the compound for use as a diagnostic marker of uterine body cancer and a method for the treatment of uterine body cancer comprising a step of carrying out the method for the diagnosis of uterine body cancer as defined above using the compound.

Abstract: The invention relates to a novel chemical compound—a diagnostic marker—for use in medicine, more specifically in cancer diagnosis, in particular the diagnosis of kidney cancer. The invention also relates to an in vitro method for detecting enzymatic activity present in a subject's body fluid, in particular derived from kidney cancer cells, using the compound. The invention further relates to an in vitro method for diagnosing kidney cancer using the compound, a kit comprising the compound and use of the compound for the detection of enzymatic activity specific to kidney cancer and use of the compound for the diagnosis of kidney cancer. The invention also relates to the compound for use as a diagnostic marker of kidney cancer and a method for the treatment of kidney cancer comprising a step of carrying out the method for the diagnosis of kidney cancer as defined above using the compound.

Abstract: The invention relates to a novel chemical compound—a diagnostic marker—for use in medicine, more specifically in cancer diagnosis, in particular the diagnosis of intestinal cancer. The invention also relates to an in vitro method for detecting enzymatic activity present in a subject's body fluid, in particular derived from intestinal cancer cells, using the compound. The invention further relates to an in vitro method for diagnosing intestinal cancer using the compound, a kit comprising the compound and use of the compound for the detection of enzymatic activity specific to intestinal cancer and use of the compound for the diagnosis of intestinal cancer. The invention also relates to the compound for use as a diagnostic marker of intestinal cancer and a method for the treatment of intestinal cancer comprising a step of carrying out the method for the diagnosis of intestinal cancer as defined above using the compound.

Abstract: The invention relates to a novel chemical compound—a diagnostic marker—for use in medicine, more specifically in cancer diagnosis, in particular the diagnosis of lung cancer. The invention also relates to an in vitro method for detecting enzymatic activity present in a subject's body fluid, in particular derived from lung cancer cells, using the compound. The invention further relates to an in vitro method for diagnosing lung cancer using the compound, a kit comprising the compound and use of the compound for the detection of enzymatic activity specific to lung cancer and use of the compound for the diagnosis of lung cancer. The invention also relates to the compound for use as a diagnostic marker of lung cancer and a method for the treatment of lung cancer comprising a step of carrying out the method for the diagnosis of lung cancer as defined above using the compound.

Abstract: The invention relates to a novel chemical compound—a diagnostic marker—for use in medicine, more specifically in cancer diagnosis, in particular the diagnosis of liver cancer. The invention also relates to an in vitro method for detecting enzymatic activity present in a subject's body fluid, in particular derived from liver cancer cells, using the compound. The invention further relates to an in vitro method for diagnosing liver cancer using the compound, a kit comprising the compound and use of the compound for the detection of enzymatic activity specific to liver cancer and use of the compound for the diagnosis of liver cancer. The invention also relates to the compound for use as a diagnostic marker of liver cancer and a method for the treatment of liver cancer comprising a step of carrying out the method for the diagnosis of liver cancer as defined above using the compound.

Abstract: The invention provides a compound characterized by formula 1: X1-Trp-Glu-Gly-Asn-X2, wherein cleavage of the compound into a fragment 1 comprising X1 and a fragment 2 comprising X2 generates a detectable signal. The invention further provides an in vitro method for detecting protease activity in a subject's body fluid, comprising contacting the body fluid with the compound of the invention and detecting a signal, wherein the body fluid may comprise a hydrolytic enzyme derived from prostate cancer cells. Furthermore, the invention provides a kit comprising the compound of the invention and a measurement buffer. In addition, the invention provides the use of the compound, the in vitro method or the kit of the invention for the detection of prostate cancer, or for monitoring a subject that is suspected of having prostate cancer, has an increased risk of developing prostate cancer, or has had prostate cancer.

Abstract: The invention provides a compound characterized by formula (1): X1-Thr-Thr-Ala-Arg-X2, wherein cleavage of the compound into a fragment 1 comprising X1 and a fragment 2 comprising X2 generates a detectable signal. The invention further provides an in vitro method for detecting protease activity in a subject's body fluid, comprising contacting the body fluid with the compound of the invention and detecting a signal, wherein the body fluid may comprise a hydrolytic enzyme derived from pancreatic cancer cells. Furthermore, the invention provides a kit comprising the compound of the invention and a measurement buffer. In addition, the invention provides the use of the compound, the in vitro method or the kit of the invention for the detection of pancreatic cancer, or for monitoring a subject that is suspected of having pancreatic cancer, has an increased risk of developing pancreatic cancer, or has had pancreatic cancer.

Abstract: The subject of the invention is a new compound of the following chemical formula: ABZ1-Dap(O2(Cbz))2-Dap(O1)3-Dap(O2)4-Arg5-ANB6-NH2 where: ABZ stands for 2-aminobenzoic acid; DAP stands for diaminopropanoic acid (Dap) derivatives, modified by the functionalised residues of mono-ethylene or diethylene glycol (PEG); ANB stands for 5-amino-2-nitrobenzoic acid The subject of the invention is a method for producing the new compound and a pharmaceutical solution for cancer detection, which contains the above-mentioned compound. The subject of the invention is a method for cancer detection through the in vitro analysis of a human urine sample to which a new compound is added and blended with a buffer of pH 7-9. The subject of the invention is also a kit for detecting cancer, in particular bladder cancer, and the use of hydrolysis of the new compound in the position no. 5 by proteasome 20s for cancer detection, in particular bladder cancer.

Abstract: The subject of the invention is a new compound of the following chemical formula: ABZ1-Dap(O2(Cbz))2-Dap(O1)3-Dap(O2)4-Arg5-ANB6-NH2 where: ABZ stands for 2-aminobenzoic acid; DAP stands for diaminopropanoic acid (Dap) derivatives, modified by the functionalised residues of mono-ethylene or diethylene glycol (PEG); ANB stands for 5-amino-2-nitrobenzoic acid The subject of the invention is a method for producing the new compound and a pharmaceutical solution for cancer detection, which contains the above-mentioned compound. The subject of the invention is a method for cancer detection through the in vitro analysis of a human urine sample to which a new compound is added and blended with a buffer of pH 7-9. The subject of the invention is also a kit for detecting cancer, in particular bladder cancer, and the use of hydrolysis of the new compound in the position no. 5 by proteasome 20s for cancer detection, in particular bladder cancer.

Abstract: The present invention relates to peptidyl phosphonate esters compounds and their use selective inhibitors of proteinase 3, in particular for treating or diagnosing inflammator autoimmune and cancer disorders. More specifically, the invention concerns nov peptidyl phosphonate esters compounds, including without limitation, compounds with Asp-Tyr-Asp-Ala or Pro-Tyr-Asp-Ala, Pro-Tyr-Asp-Avl, Val-Tyr-Asp-Avl peptide structure or their derivatives.